Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Vickers

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Medicinal Chemistry|June 25, 2005
Positional effect of chemical modifications on short interference RNA activity in mammalian cellsThazha P Prakash, Charles R Allerson, Prasad Dande, et al.
The Journal of Clinical Investigation|March 22, 2016
Modulation of LMNA splicing as a strategy to treat prelamin A diseasesJohn M Lee, Chika Nobumori, Yiping Tu, et al.
Human Molecular Genetics|April 21, 2009
Activating the synthesis of progerin, the mutant prelamin A in Hutchinson-Gilford progeria syndrome, with antisense oligonucleotidesLoren G Fong, Timothy A Vickers, Emily A Farber, et al.
The Journal of Clinical Investigation|March 3, 2006
Prelamin A and lamin A appear to be dispensable in the nuclear laminaLoren G Fong, Jennifer K Ng, Jan Lammerding, et al.
Journal of Medicinal Chemistry|April 28, 2010
Peptide nucleic acids conjugated to short basic peptides show improved pharmacokinetics and antisense activity in adipose tissueEdward V Wancewicz, Martin A Maier, Andrew M Siwkowski, et al.
Nature Biotechnology|May 1, 2019
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic indexWen Shen, Cheryl L De Hoyos, Michael T Migawa, et al.
Nucleic Acids Research|August 21, 2021
Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotidesBrooke A Anderson, Graeme C Freestone, Audrey Low, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Medicinal Chemistry|June 25, 2005
Positional effect of chemical modifications on short interference RNA activity in mammalian cellsThazha P Prakash, Charles R Allerson, Prasad Dande, et al.
The Journal of Clinical Investigation|March 22, 2016
Modulation of LMNA splicing as a strategy to treat prelamin A diseasesJohn M Lee, Chika Nobumori, Yiping Tu, et al.
Human Molecular Genetics|April 21, 2009
Activating the synthesis of progerin, the mutant prelamin A in Hutchinson-Gilford progeria syndrome, with antisense oligonucleotidesLoren G Fong, Timothy A Vickers, Emily A Farber, et al.
The Journal of Clinical Investigation|March 3, 2006
Prelamin A and lamin A appear to be dispensable in the nuclear laminaLoren G Fong, Jennifer K Ng, Jan Lammerding, et al.
Journal of Medicinal Chemistry|April 28, 2010
Peptide nucleic acids conjugated to short basic peptides show improved pharmacokinetics and antisense activity in adipose tissueEdward V Wancewicz, Martin A Maier, Andrew M Siwkowski, et al.
Nature Biotechnology|May 1, 2019
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic indexWen Shen, Cheryl L De Hoyos, Michael T Migawa, et al.
Nucleic Acids Research|August 21, 2021
Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotidesBrooke A Anderson, Graeme C Freestone, Audrey Low, et al.
Pageof 4